Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCancell Therapeutics, a biotechnology company, has planned to begin patient enrollment for its Phase IIb pancreatic cancer clinical trial.
Subscribe to our email newsletter
The trial will evaluate the efficacy of BioCancell’s BC-819 in sequence with Gemcitabine, in treating locally-advanced, unresectable pancreatic cancer. pbpb
About 100 participants are expected to be enrolled in multiple medical centers in Europe, Israel and the US.
Half of the participants will be treated with the combination of BioCancell’s BC-819 and Gemcitabine, and the other half will be treated with Gemcitabine alone.
The primary endpoint of the trial is progression-free survival, while secondary objectives comprise overall survival, response rate and resectability of the target tumor lesion.